Executive Summary
Summary PIQUR Therapeutics AG (PIQUR) is a developer of anti-cancer drugs. The company develops innovative small molecule therapeutics based on lipid kinase (PI3K) and mTOR inhibitior for the treatment of cancer and inflammatory diseases. Its pipeline products comprise PQR-309, PQR-620, PQR-530, PQR-514, PQR-6XX, and PI3K/mTOR inhibitors. PIQUR's lead compound PQR309, is a potent small molecule with balanced pan-PI3KmTOR selectivity. PIQUR's target therapy areas include oncology, central nervous system, ophthalmology, and dermatology, among others. The company conducts research in the areas of oncology. It serves patients and the medical communities across Switzerland. PIQUR is headquartered in Basel, Switzerland. PIQUR Therapeutics AG-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions. GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research. Scope - Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios. - Business Description-A brief description of the company's operations. - Key Employees-A list of the key executives of the company. - Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors-A list of the key competitors of the company. - Key Recent Developments-A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements - The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy - The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. - The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company.
Read More
Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
Table of Contents Table of Contents 3 List of Tables 4 List of Figures 4 PIQUR Therapeutics AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5 PIQUR Therapeutics AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6 PIQUR Therapeutics AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7 PIQUR Therapeutics AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8 PIQUR Therapeutics AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9 PIQUR Therapeutics AG, Pharmaceuticals & Healthcare, Deal Details 10 Venture Financing 10 PIQUR Therapeutics Raises USD19 Million in Series A2 Financing 10 PIQUR Therapeutics Raises Additional USD 16 Million In Series A Financing 11 PIQUR Therapeutics Raises USD 20 Million In Series A Financing 12 PIQUR Therapeutics Raises Funds in Extended Seed Financing 13 PIQUR Therapeutics Raises USD5.5 Million in Seed Financing 14 Partnerships 15 Laboratoires Pierre Fabre Enters into Licensing Agreement with PIQUR Therapeutics 15 Eisai Enters into Agreement with PIQUR Therapeutics 16 Licensing Agreements 17 PIQUR Therapeutics Expands Licensing Agreement with University of Basel for PQR309 17 PIQUR Therapeutics AG-Key Competitors 18 PIQUR Therapeutics AG-Key Employees 19 PIQUR Therapeutics AG-Locations And Subsidiaries 20 Head Office 20 Recent Developments 21 Product Approvals 21 Apr 27, 2017: PIQUR Receives EMA Orphan Drug Designation for PQR309 in Diffuse Large B-Cell Lymphoma 21 Appendix 22 Methodology 22 About GlobalData 22 Contact Us 22 Disclaimer 22
List of Tables PIQUR Therapeutics AG, Pharmaceuticals & Healthcare, Key Facts 2 PIQUR Therapeutics AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5 PIQUR Therapeutics AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6 PIQUR Therapeutics AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7 PIQUR Therapeutics AG, Deals By Therapy Area, 2012 to YTD 2018 8 PIQUR Therapeutics AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9 PIQUR Therapeutics Raises USD19 Million in Series A2 Financing 10 PIQUR Therapeutics Raises Additional USD 16 Million In Series A Financing 11 PIQUR Therapeutics Raises USD 20 Million In Series A Financing 12 PIQUR Therapeutics Raises Funds in Extended Seed Financing 13 PIQUR Therapeutics Raises USD5.5 Million in Seed Financing 14 Laboratoires Pierre Fabre Enters into Licensing Agreement with PIQUR Therapeutics 15 Eisai Enters into Agreement with PIQUR Therapeutics 16 PIQUR Therapeutics Expands Licensing Agreement with University of Basel for PQR309 17 PIQUR Therapeutics AG, Key Competitors 18 PIQUR Therapeutics AG, Key Employees 19
Single User License:
Report can be used by individual purchaser only
Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office
Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company
PIQUR Therapeutics AG, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
|
Agriculture and Animal Care
Automotive, Transportation and Warehousing
Banking Financial Services and Insurance
Consumer Products and Retail
Defense and Security
Education and Recruitment
Energy and Utilities
Food, Beverage and Tobacco
Healthcare
Manufacturing and Construction
Media and Entertainment
Metal, Mining and Chemicals
Public Sector and Administration
Technology and Telecom
